Welcome to our dedicated page for Arvinas news (Ticker: ARVN), a resource for investors and traders seeking the latest updates and insights on Arvinas stock.
Arvinas, Inc. develops targeted protein degradation medicines through its PROTAC protein degrader platform. Company updates center on VEPPANU (vepdegestrant), developed with Pfizer and approved by the FDA for adults with ER+/HER2-, ESR1-mutated advanced or metastatic breast cancer after endocrine-based therapy, as well as regulatory, clinical, and corporate milestones tied to that program.
Arvinas news also covers investigational PROTAC degraders across oncology, neurology, and neuromuscular disease, including ARV-102 for LRRK2-driven neurodegenerative disorders, ARV-806 for KRAS G12D-mutated cancers, ARV-393 for BCL6-driven lymphoma, and ARV-027 as a polyQ-AR degrader. Recurring items include clinical data presentations, financial results, corporate updates, investor conferences, and governance changes.
Arvinas, a clinical-stage biotechnology company, announced a $25,000 Early Career Research Award to honor 20 years of targeted protein degradation. This award aims to recognize innovative research efforts in the field, with nominations open until August 1, 2022. The winner will be presented at the 5th Annual Targeted Protein Degradation Summit in October 2022. Arvinas emphasizes its commitment to advancing biotechnology through innovative therapies that degrade disease-causing proteins.
GNS Healthcare announced a collaboration with Arvinas (ARVN) aimed at accelerating drug development for neurodegenerative diseases. By utilizing GNS' Gemini Virtual Patient models, Arvinas seeks to gain insights into disease progression, enhancing drug candidate selection and clinical trial efficiency. With over six million new diagnoses of Alzheimer's, Parkinson's, and Huntington's diseases annually in the U.S., this partnership intends to improve patient outcomes through targeted protein degradation therapies. Both companies emphasize a commitment to advancing treatment options for these chronic conditions.
Arvinas, Inc. (Nasdaq: ARVN) reported its Q1 2022 financial results, highlighting a productive quarter with plans for three pivotal clinical trials in 2022. Revenue surged to $24.2 million, up from $5.5 million in Q1 2021, driven by collaborations, particularly the ARV-471 program. However, net loss increased to $63.4 million from $41.0 million, primarily due to rising R&D and administrative costs. Cash reserves decreased to $1.43 billion. Key milestones include ongoing trials for ARV-471 and bavdegalutamide while preparing for potential FDA discussions.
Arvinas, a clinical-stage biotechnology company, announced participation in the Bank of America Securities 2022 Healthcare Conference on May 10 at 7:00 p.m. ET in Las Vegas. The event will feature a fireside chat with management, and a live audio webcast will be available on the company's website. Arvinas specializes in targeted protein degradation therapies, utilizing its proprietary PROTAC® Discovery Engine platform. The company has three clinical-stage programs focused on various cancers, including prostate and breast cancer.
Arvinas, a clinical-stage biotechnology company, announced participation in two virtual investor conferences. The first is the Cowen & Co. 42nd Annual Health Care Conference on March 7, featuring a fireside chat with Chief Scientific Officer Ian Taylor. The second event is the Guggenheim Targeted Protein Degradation Day on March 16, also with Taylor. Arvinas focuses on developing therapies that degrade disease-causing proteins using its PROTAC technology. The company has three clinical-stage programs targeting advanced prostate and breast cancer.
Arvinas, Inc. (Nasdaq: ARVN) reported its financial results for Q4 and the full year 2021, highlighting significant advancements in its drug development pipeline and a strong collaboration with Pfizer.
The company reported revenues of $46.7 million for 2021, up from $21.8 million in 2020, primarily driven by the ARV-471 collaboration. However, the net loss increased to $191 million due to rising R&D costs of $180.4 million. Key milestones are anticipated in 2022 for both ARV-471 and bavdegalutamide, including pivotal trials.
Arvinas, Inc. (Nasdaq: ARVN) announced promising Phase 1 and interim Phase 2 data for its investigational drug bavdegalutamide (ARV-110), targeting metastatic castration-resistant prostate cancer (mCRPC). The treatment showed a 46% prostate-specific antigen (PSA)50 response rate in patients with specific androgen receptor mutations. Additionally, two patients had confirmed durable tumor responses. Arvinas plans to seek FDA discussions for an accelerated approval pathway and aims to initiate a pivotal trial by the end of 2022.
Cardurion Pharmaceuticals has appointed Marcia Moore as Chief Operating Officer. With over 30 years in the pharmaceutical and biotechnology sectors, Moore joins from Arvinas (NASDAQ: ARVN), where she played a crucial role in strategic operations and clinical development. Her expertise includes managing clinical trials and regulatory strategies, enhancing Cardurion’s pipeline of cardiovascular drug candidates, including a $300 million investment from Bain Capital to fuel growth. CEO Peter Lawrence expressed confidence in Moore’s leadership at this pivotal time.
Arvinas announced promising data for bavdegalutamide, showing a 46% PSA50 rate in patients with metastatic castration-resistant prostate cancer (mCRPC) with AR T878X/H875Y mutations. A pivotal trial is set to begin by year-end 2022, targeting patients who have progressed after novel hormonal agents. Updated data will be presented at the ASCO GU symposium, and a webcast will follow on February 17, 2022.
Arvinas, a clinical-stage biotechnology company focused on targeted protein degradation, will participate in two virtual investor conferences in February 2022. The first is the Guggenheim Oncology Conference on February 10, featuring Chief Scientific Officer Ian Taylor. The second is the 2022 SVB Leerink Global Healthcare Conference on February 18, with insights from President and CEO John Houston. Live webcasts of both presentations will be accessible on the company's website.
Arvinas aims to revolutionize treatments for serious diseases through innovative therapies targeting disease-causing proteins.